Efficacy and Prognosis Analysis of PD-1 Inhibitor Combined with GP Regimen in the Treatment of Patients with Advanced Triple-Negative Breast Cancer

Kaiyuan Zhu, Qing Lv and Jinpeng Qiao

Background and Objective: Advanced Triple-Negative Breast Cancer (TNBC) exhibits suboptimal sensitivity to endocrine therapies, coupled with availability of limited targeted agents, posing considerable challenges to clinical management. To explore the efficacy and prognosis of Programmed Cell Death Protein-1 (PD-1) inhibitor combined with the GP regimen in the treatment of patients with advanced TNBC. Materials and Methods: A retrospective analysis was conducted on the clinical data of 87 advanced TNBC patients who underwent treatment in hospital from September 2020 to August 2022. The patients were divided into two groups based on different treatment regimens, including a control group (n = 45, treated with the GP regimen) and a study group (n = 42, received combination therapy of camrelizumab and the GP regimen). The clinical efficacy, tumor markers (CEA, CA125 and CA15-3), immune function (levels of CD3⁺, CD4⁺, CD8⁺ and CD4⁺/CD8⁺), angiogenic factors (MMP-9, VEGF and TGF-β1), quality of life (WHOQOL-BREF scale scores), adverse reactions and survival outcomes (PFS, OS) were compared between the two groups. Results: The study group exhibited significantly higher overall efficacy compared to the control group (p<0.05). After treatment, the levels of CEA, CA125 and CA15-3 markedly decreased in both groups, with the study group demonstrating even lower levels (p<0.05). After treatment, CD3⁺, CD4⁺ and CD4⁺/CD8⁺ levels significantly increased in both groups, while CD8⁺ levels notably decreased, with the study group showing more pronounced improvements (p<0.05). After treatment, the levels of MMP-9, VEGF and TGF-β1 significantly decreased in both groups, with the study group exhibiting even lower levels (p<0.05). After treatment, scores on various dimensions of the WHOQOL-BREF scale notably increased in both groups, with the study group demonstrating higher scores (p<0.05). The incidence of adverse reactions did not exhibit significant differences between the two groups (p>0.05). The study group displayed superior PFS and OS compared to the control group (p<0.05). Conclusion: The combination of PD-1 inhibitor and GP regimen demonstrated precise therapeutic efficacy in the treatment of advanced TNBC, which facilitated the restoration of patients’ immune function, reduced tumor marker levels, suppressed tumor angiogenesis, promoted enhancement in quality of life, improved short-term prognosis and exhibited favorable safety profile.

View Fulltext Back